Finding 1076472 (2023-001)

Material Weakness
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-09-30
Audit: 322924

AI Summary

  • Core Issue: Lack of effective internal controls over federal awards as required by Section 200.303 of the Uniform Guidance.
  • Impacted Requirements: Compliance with federal statutes and regulations, specifically regarding the management of federal awards and preparation of expenditure schedules.
  • Recommended Follow-Up: Implement stronger internal controls and ensure accurate reporting of federal expenditures to meet compliance standards.

Finding Text

Finding 2023-001 – Reporting Information of the federal program: Federal Grantor: Department of Defense (DOD) Assistance Listing No.: 12.420, Military Medical Research and Development Pass-Through Grantor: Johns Hopkins University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.172, Human Genome Research Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.226, Research on Healthcare Costs, Quality and Outcomes Pass-Through Grantor: The Regents of the University of Michigan Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.242, Mental Health Research Grants Pass-Through Grantor: Rutgers State University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.307, Minority Health and Health Disparities Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.310, Trans-NIH Research Support Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.350, National Center for Advancing Translational Sciences Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.351, Research Infrastructure Program Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.361, Nursing Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.368, 21st Century Cures Act – Precision Medicine Initiative Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.394, Cancer Detection and Diagnosis Research Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.395, Cancer Treatment Research Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.396, Cancer Biology Research Pass-Through Grantor: Tulane University, Louisiana State University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.397, Cancer Centers Support Grants Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.667, Social Services Block Grant Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.837, Cardiovascular Diseases Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.838, Lung Diseases Research Pass-Through Grantor: Northwestern University   Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research Pass-Through Grantors: Northwestern University, Duke University, University of Washington, The Regents of University of Michigan Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders Pass-Through Grantor: Rush University Medical Center Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.855, Allergy, Immunology and Transplantation Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.859, Biomedical Research and Research Training Pass-Through Grantor: University of Wisconsin – Madison Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.865, Child Health and Human Development Extramural Research Pass-Through Grantors: Northwestern University, University of Washington, The Regents of the University of California Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.866, Aging Research Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.946, Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.994, Maternal and Child Health Services Block Grant to the States Pass-Through Grantor: Northwestern Memorial Hospital Criteria or specific requirement (including statutory, regulatory, or other citation): Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).” The Uniform Guidance 2 CFR section 200.510 states, “(b) Schedule of expenditures of Federal awards. The auditee must also prepare a schedule of expenditures of federal awards (SEFA) for the period covered by the auditee’s financial statements which must include the total Federal awards expended as determined in accordance with §200.502 Basis for determining Federal awards expended.” Condition: Certain grants related to the Research and Development Cluster were misstated by $233,405 on the preliminary schedule of expenditures of federal awards (the Schedule) provided by management due to the inappropriate classification of costs within the general ledger; the final Schedule was corrected. In addition, an award which was not a federal grant award with expenditures of $148,388 was included on the preliminary Schedule provided by management. The final Schedule was corrected. Cause: Endeavor’s internal controls over the preparation of the Schedule were not sufficient to properly accumulate and accurately report all expenditures of federal awards. Effect or Potential Effect: Inaccurate or improper reporting of expenditures results in a misstated Schedule and can also potentially result in insufficient testing of the major programs or improper identification of major programs for audit purposes. Questioned costs: None. Context: The table below reflects the preliminary and adjusted assistance listing balances on the Schedule (only assistance listing programs which changed are included below): Assistance Listing No. Name of Federal Program Preliminary Schedule Adjusted Schedule Change 12.420 Military Medical Research and Development $ 241,025 $ 224,418 $ 16,607 93.172 Human Genome Research 14,874 15,121 (247) 93.226 Research on Healthcare Costs, Quality and Outcomes 251,325 248,842 2,483 93.242 Mental Health Research Grants 1,616,503 1,617,376 (873) 93.307 Minority Health and Health Disparities Research 17,323 15,122 2,201 93.310 Trans-NIH Research Support 313,459 313,490 (31) 93.350 National Center for Advancing Translational Sciences 516,734 518,429 (1,695) 93.351 Research Infrastructure Program 242,436 232,058 10,378 93.361 Nursing Research 8,745 7,645 1,100 93.368 21st Century Cures Act – Precision Medicine Initiative 100,324 94,609 5,715 93.394 Cancer Detection and Diagnosis Research 847,959 816,528 31,431 93.395 Cancer Treatment Research 438,349 439,286 (937) 93.396 Cancer Biology Research 93,919 88,642 5,277 93.397 Cancer Centers Support Grants 15,552 14,078 1,474 93.667 Social Services Block Grant 19,619 27,170 (7,551) 93.837 Cardiovascular Diseases Research 193,160 188,850 4,310 93.838 Lung Diseases Research 482,934 471,427 11,507 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 1,075,493 1,035,041 40,452 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 1,645,025 1,596,611 48,414 93.855 Allergy, Immunology and Transplantation Research 73,869 72,630 1,239 93.859 Biomedical Research and Research Training 363,336 366,791 (3,455) 93.865 Child Health and Human Development Extramural Research 3,790,797 3,733,008 57,789 93.866 Aging Research 1,101,363 1,098,891 2,472 93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs 80,039 78,033 2,006 93.994 Maternal and Child Health Services Block Grant to the States 171,995 168,656 3,339 The Role of Oral Care in Nonventilator Hospital-Acquired Pneumonia (NVHAP) Prevention 148,388 – 148,388 Total $ 13,864,545 $ 13,482,752 $ 381,793 Identification as a repeat finding, if applicable: The finding is not a repeat finding from the prior year. Recommendation: Management should implement internal controls to ensure amounts are appropriately accumulated and reported on the Schedule and all federal expenditures are appropriately identified and reported on the Schedule. Views of responsible officials: Award amounts were changed on the Schedule after management’s review was executed. Management acknowledges that implementing the new Enterprise Resource Planning (ERP) system, in 2023 presented changes to the SEFA reporting. Management has identified and addressed the reporting issues within the new system to ensure that the grant totals are appropriately captured in the SEFA. Endeavor will enhance grant management award processes by revising its procedures and adding additional controls to monitor for accuracy of the core data. Management will reinforce the importance of timeliness and accuracy of the Schedule reporting totals to facilitate accurate reporting.

Categories

Reporting

Other Findings in this Audit

  • 499999 2023-001
    Material Weakness
  • 500000 2023-002
    Material Weakness
  • 500001 2023-001
    Material Weakness
  • 500002 2023-002
    Material Weakness
  • 500003 2023-001
    Material Weakness
  • 500004 2023-005
    Significant Deficiency
  • 500005 2023-001
    Material Weakness
  • 500006 2023-005
    Significant Deficiency
  • 500007 2023-001
    Material Weakness
  • 500008 2023-002
    Material Weakness
  • 500009 2023-005
    Significant Deficiency
  • 500010 2023-005
    Significant Deficiency
  • 500011 2023-001
    Material Weakness
  • 500012 2023-005
    Significant Deficiency
  • 500013 2023-001
    Material Weakness
  • 500014 2023-001
    Material Weakness
  • 500015 2023-002
    Material Weakness
  • 500016 2023-005
    Significant Deficiency
  • 500017 2023-001
    Material Weakness
  • 500018 2023-002
    Material Weakness
  • 500019 2023-005
    Significant Deficiency
  • 500020 2023-005
    Significant Deficiency
  • 500021 2023-001
    Material Weakness
  • 500022 2023-001
    Material Weakness
  • 500023 2023-005
    Significant Deficiency
  • 500024 2023-001
    Material Weakness
  • 500025 2023-002
    Material Weakness
  • 500026 2023-004
    Material Weakness
  • 500027 2023-001
    Material Weakness
  • 500028 2023-001
    Material Weakness
  • 500029 2023-005
    Significant Deficiency
  • 500030 2023-001
    Material Weakness
  • 500031 2023-005
    Significant Deficiency
  • 500032 2023-001
    Material Weakness
  • 500033 2023-005
    Significant Deficiency
  • 500034 2023-001
    Material Weakness
  • 500035 2023-005
    Significant Deficiency
  • 500036 2023-001
    Material Weakness
  • 500037 2023-005
    Significant Deficiency
  • 500038 2023-001
    Material Weakness
  • 500039 2023-005
    Significant Deficiency
  • 500040 2023-001
    Material Weakness
  • 500041 2023-005
    Significant Deficiency
  • 500042 2023-001
    Material Weakness
  • 500043 2023-005
    Significant Deficiency
  • 500044 2023-001
    Material Weakness
  • 500045 2023-005
    Significant Deficiency
  • 500046 2023-001
    Material Weakness
  • 500047 2023-005
    Significant Deficiency
  • 500048 2023-001
    Material Weakness
  • 500049 2023-005
    Significant Deficiency
  • 500050 2023-001
    Material Weakness
  • 500051 2023-005
    Significant Deficiency
  • 500052 2023-001
    Material Weakness
  • 500053 2023-001
    Material Weakness
  • 500054 2023-001
    Material Weakness
  • 500055 2023-001
    Material Weakness
  • 500056 2023-001
    Material Weakness
  • 500057 2023-001
    Material Weakness
  • 500058 2023-002
    Material Weakness
  • 500059 2023-003
    Material Weakness
  • 500060 2023-002
    Material Weakness
  • 500061 2023-001
    Material Weakness
  • 500062 2023-001
    Material Weakness
  • 500063 2023-005
    Significant Deficiency
  • 500064 2023-001
    Material Weakness
  • 500065 2023-005
    Significant Deficiency
  • 500066 2023-001
    Material Weakness
  • 500067 2023-005
    Significant Deficiency
  • 500068 2023-001
    Material Weakness
  • 500069 2023-002
    Material Weakness
  • 500070 2023-005
    Significant Deficiency
  • 500071 2023-001
    Material Weakness
  • 500072 2023-005
    Significant Deficiency
  • 500073 2023-001
    Material Weakness
  • 500074 2023-005
    Significant Deficiency
  • 500075 2023-001
    Material Weakness
  • 500076 2023-002
    Material Weakness
  • 500077 2023-001
    Material Weakness
  • 500078 2023-002
    Material Weakness
  • 500079 2023-001
    Material Weakness
  • 500080 2023-005
    Significant Deficiency
  • 500081 2023-002
    Material Weakness
  • 500082 2023-001
    Material Weakness
  • 500083 2023-002
    Material Weakness
  • 500084 2023-001
    Material Weakness
  • 500085 2023-001
    Material Weakness
  • 500086 2023-001
    Material Weakness
  • 500087 2023-005
    Significant Deficiency
  • 500088 2023-001
    Material Weakness
  • 500089 2023-001
    Material Weakness
  • 500090 2023-003
    Material Weakness
  • 500091 2023-001
    Material Weakness
  • 500092 2023-002
    Material Weakness
  • 500093 2023-005
    Significant Deficiency
  • 500094 2023-001
    Material Weakness
  • 500095 2023-002
    Material Weakness
  • 500096 2023-005
    Significant Deficiency
  • 500097 2023-001
    Material Weakness
  • 1076441 2023-001
    Material Weakness
  • 1076442 2023-002
    Material Weakness
  • 1076443 2023-001
    Material Weakness
  • 1076444 2023-002
    Material Weakness
  • 1076445 2023-001
    Material Weakness
  • 1076446 2023-005
    Significant Deficiency
  • 1076447 2023-001
    Material Weakness
  • 1076448 2023-005
    Significant Deficiency
  • 1076449 2023-001
    Material Weakness
  • 1076450 2023-002
    Material Weakness
  • 1076451 2023-005
    Significant Deficiency
  • 1076452 2023-005
    Significant Deficiency
  • 1076453 2023-001
    Material Weakness
  • 1076454 2023-005
    Significant Deficiency
  • 1076455 2023-001
    Material Weakness
  • 1076456 2023-001
    Material Weakness
  • 1076457 2023-002
    Material Weakness
  • 1076458 2023-005
    Significant Deficiency
  • 1076459 2023-001
    Material Weakness
  • 1076460 2023-002
    Material Weakness
  • 1076461 2023-005
    Significant Deficiency
  • 1076462 2023-005
    Significant Deficiency
  • 1076463 2023-001
    Material Weakness
  • 1076464 2023-001
    Material Weakness
  • 1076465 2023-005
    Significant Deficiency
  • 1076466 2023-001
    Material Weakness
  • 1076467 2023-002
    Material Weakness
  • 1076468 2023-004
    Material Weakness
  • 1076469 2023-001
    Material Weakness
  • 1076470 2023-001
    Material Weakness
  • 1076471 2023-005
    Significant Deficiency
  • 1076473 2023-005
    Significant Deficiency
  • 1076474 2023-001
    Material Weakness
  • 1076475 2023-005
    Significant Deficiency
  • 1076476 2023-001
    Material Weakness
  • 1076477 2023-005
    Significant Deficiency
  • 1076478 2023-001
    Material Weakness
  • 1076479 2023-005
    Significant Deficiency
  • 1076480 2023-001
    Material Weakness
  • 1076481 2023-005
    Significant Deficiency
  • 1076482 2023-001
    Material Weakness
  • 1076483 2023-005
    Significant Deficiency
  • 1076484 2023-001
    Material Weakness
  • 1076485 2023-005
    Significant Deficiency
  • 1076486 2023-001
    Material Weakness
  • 1076487 2023-005
    Significant Deficiency
  • 1076488 2023-001
    Material Weakness
  • 1076489 2023-005
    Significant Deficiency
  • 1076490 2023-001
    Material Weakness
  • 1076491 2023-005
    Significant Deficiency
  • 1076492 2023-001
    Material Weakness
  • 1076493 2023-005
    Significant Deficiency
  • 1076494 2023-001
    Material Weakness
  • 1076495 2023-001
    Material Weakness
  • 1076496 2023-001
    Material Weakness
  • 1076497 2023-001
    Material Weakness
  • 1076498 2023-001
    Material Weakness
  • 1076499 2023-001
    Material Weakness
  • 1076500 2023-002
    Material Weakness
  • 1076501 2023-003
    Material Weakness
  • 1076502 2023-002
    Material Weakness
  • 1076503 2023-001
    Material Weakness
  • 1076504 2023-001
    Material Weakness
  • 1076505 2023-005
    Significant Deficiency
  • 1076506 2023-001
    Material Weakness
  • 1076507 2023-005
    Significant Deficiency
  • 1076508 2023-001
    Material Weakness
  • 1076509 2023-005
    Significant Deficiency
  • 1076510 2023-001
    Material Weakness
  • 1076511 2023-002
    Material Weakness
  • 1076512 2023-005
    Significant Deficiency
  • 1076513 2023-001
    Material Weakness
  • 1076514 2023-005
    Significant Deficiency
  • 1076515 2023-001
    Material Weakness
  • 1076516 2023-005
    Significant Deficiency
  • 1076517 2023-001
    Material Weakness
  • 1076518 2023-002
    Material Weakness
  • 1076519 2023-001
    Material Weakness
  • 1076520 2023-002
    Material Weakness
  • 1076521 2023-001
    Material Weakness
  • 1076522 2023-005
    Significant Deficiency
  • 1076523 2023-002
    Material Weakness
  • 1076524 2023-001
    Material Weakness
  • 1076525 2023-002
    Material Weakness
  • 1076526 2023-001
    Material Weakness
  • 1076527 2023-001
    Material Weakness
  • 1076528 2023-001
    Material Weakness
  • 1076529 2023-005
    Significant Deficiency
  • 1076530 2023-001
    Material Weakness
  • 1076531 2023-001
    Material Weakness
  • 1076532 2023-003
    Material Weakness
  • 1076533 2023-001
    Material Weakness
  • 1076534 2023-002
    Material Weakness
  • 1076535 2023-005
    Significant Deficiency
  • 1076536 2023-001
    Material Weakness
  • 1076537 2023-002
    Material Weakness
  • 1076538 2023-005
    Significant Deficiency
  • 1076539 2023-001
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crisis $1.26M
93.394 Cancer Detection and Diagnosis Research $816,528
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $609,195
93.310 Trans-Nih Research Support $313,490
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $187,525
93.994 Maternal and Child Health Services Block Grant to the States $168,656
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $167,045
93.350 National Center for Advancing Translational Sciences $164,703
93.368 21st Century Cures Act - Precision Medicine Initiative $94,609
93.838 Lung Diseases Research $93,061
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $80,571
93.855 Allergy and Infectious Diseases Research $72,630
93.351 Research Infrastructure Programs $67,407
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $64,097
93.396 Cancer Biology Research $56,813
12.420 Military Medical Research and Development $55,493
93.226 Research on Healthcare Costs, Quality and Outcomes $36,564
93.865 Child Health and Human Development Extramural Research $29,653
93.393 Cancer Cause and Prevention Research $17,681
93.307 Minority Health and Health Disparities Research $15,122
93.172 Human Genome Research $15,121
93.397 Cancer Centers Support Grants $14,078
93.889 National Bioterrorism Hospital Preparedness Program $13,333
93.866 Aging Research $11,855
93.273 Alcohol Research Programs $10,732
14.218 Community Development Block Grants/entitlement Grants $10,044
93.837 Cardiovascular Diseases Research $8,921
93.361 Nursing Research $7,645
93.667 Social Services Block Grant $7,551
93.839 Blood Diseases and Resources Research $3,217
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $597
93.395 Cancer Treatment Research $512
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $-697
93.859 Biomedical Research and Research Training $-2,184
93.242 Mental Health Research Grants $-20,481